ReviewAnnals of medicine2025
The role of neutrophils in bronchiectasis.
Review in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Comparison of clinical and microbiological features between mucoid and non-mucoidMicrobiology spectrum · 2026Article
- Brensocatib-Another Therapeutic "Window of Opportunity" for Patients with Bronchiectasis.Journal of clinical medicine · 2026Review
- Serum albumin, NLR and PLR in pre-treatment assessment of bronchiectasis exacerbations.Bioinformation · 2026Article
- The convergent pathway of obstructive lung disease: the disease-modifying potential of dipeptidyl peptidase 1 inhibition in COPD, asthma and bronchiectasis overlap.Drugs in context · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeutrophils are pivotal inflammatory cells in bronchiectasis pathophysiology, yet their stage-specific roles remain incompletely understood. This review synthesizes evidence on neutrophil activation across disease stages and explores therapeutic implications.
methodsWe performed a thorough literature review analyzing neutrophil behavior in bronchiectasis, focusing on proliferation, activation, and their contributions to tissue damage during the early and middle stages and analyzing their behavior and its correlation with disease progression. To ensure a comprehensive review of the literature on the role of neutrophils in bronchiectasis, we conducted a systematic search using the following databases: PubMed, Embase, and Web of Science. The search terms included 'neutrophils,' 'bronchiectasis,' 'neutrophil elastase,' 'bronchiectasis treatment,' and 'neutrophilic inflammation'. The search period covered articles published from January 2000 to June 2024. We also reviewed the reference lists of relevant articles to identify additional studies.
resultsNeutrophils demonstrated significant proliferation and activation during the early and middle stages of bronchiectasis, leading to the release of inflammatory mediators and an exacerbation of tissue damage. In particular, neutrophil activation during the middle stage of the disease was significantly positively correlated with the destruction of bronchial tissue. Furthermore, inhibiting neutrophil activation markedly reduced the release of inflammatory factors and improved the integrity of bronchial epithelial cells.
conclusionsThis study highlights the role of neutrophil activation at different stages of bronchiectasis and suggests that targeting neutrophil activation may represent a promising therapeutic strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.